Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

3.6.1.9: nucleotide diphosphatase

This is an abbreviated version!
For detailed information about nucleotide diphosphatase, go to the full flat file.

Word Map on EC 3.6.1.9

Reaction

a nucleoside triphosphate
+
H2O
=
A nucleotide
 +
diphosphate

Synonyms

ADPglucose pyrophosphatase/phosphodiesterase, AGPPase, AGPPase1, AGPPase2, alkaline sphingomyelinase nucleotide pyrophosphatase phosphodiesterase 7, Apyrase, ASMTL-Maf, BSU28050, CBS-PPase, CBS-pyrophosphatase, CD203c, CD39, diphosphopyridine nucleotide pyrophosphatase, dITP pyrophosphatase, dITPase, E-NPP, E-NPP1, E-NPP3, E-NTPDase, E-type ATPDase, EC 3.6.1.19, ecto-ATP-diphosphohydrolase, ecto-ATPDase, ecto-nucleoside triphosphate diphosphohydrolase, ecto-nucleoside triphosphate diphosphohydrolase 2, ecto-nucleotide phosphodiesterase/pyrophosphatase 6 eNPP6, ecto-nucleotide pyrophosphatase, ecto-nucleotide pyrophosphatase/phosphodiesterase, ecto-nucleotide pyrophosphatase/phosphodiesterase I-3, ecto-nucleotide pyrophosphatase/phosphodiesterase1, ecto-nucleotide pyrophosphatase/phosphodiesterase3, ecto-nucleotide pyrophosphatase/phosphodiesterases, ectonucleotide pyrophosphatase/phosphodiesterase, ectonucleotide pyrophosphatase/phosphodiesterase 1, ectonucleotide pyrophosphatase/phosphodiesterase family member 3, ENPP1, ENPP3, ENTPD1, Entpd6, family II pyrophosphatase, h-NPP-1, h-NPP-3, h-NPP1, h-NPP3, HAM1, inosine triphosphatase, inosine triphosphate pyrophosphatase, inosine triphosphate pyrophosphohydrolase, ITPA, ITPase, Maf protein, Maf-like protein YhdE, MazG, MazG protein, MazG-related protein, More, MutT, NPP, NPP 1, NPP 2, NPP 3, NPP-5, NPP1, NPP2, NPP3, NPP6, NPP7, NPPase, NPPr, NTPDase, nucleoside triphosphate diphosphatase, nucleoside triphosphate diphosphohydrolase, nucleoside triphosphate pyrophosphatase, nucleoside triphosphate pyrophosphohydrolase, nucleoside-triphosphate pyrophosphatase, nucleotide pyrophosphastases/phosphodiesterases1, nucleotide pyrophosphastases/phosphodiesterases3, nucleotide pyrophosphatase, nucleotide pyrophosphatase-1, nucleotide pyrophosphatase-3, nucleotide pyrophosphatase-5, nucleotide pyrophosphatase/phosphodiesterase, nucleotide pyrophosphatase/phosphodiesterase 1, nucleotide pyrophosphatase/phosphodiesterase NPP1, nucleotide pyrophosphatase/phosphodiesterase-1, nucleotide pyrophosphatase/phosphodiesterase-I, nucleotide pyrophosphatase/phosphodiesterases, nucleotide pyrophosphohydrolase, nucleotide-sugar pyrophosphatase, nucleotide-sugar pyrophosphatase/phosphodiesterase, ONPP, PC-1, plasma cell membrane glycoprotein-1, PPase, pyrophosphatase, nucleoside triphosphate, RdgB, RS21-C6, SAGPPase1, SAGPPase2, Tm-MazG, TM0159, TM0913, YhdE, YJR069C, YOR111W, ZmNPP1, ZmNPP2, ZmNPP3

ECTree

     3 Hydrolases
         3.6 Acting on acid anhydrides
             3.6.1 In phosphorus-containing anhydrides
                3.6.1.9 nucleotide diphosphatase

Inhibitors

Inhibitors on EC 3.6.1.9 - nucleotide diphosphatase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(2E)-2-([3-methoxy-4-[(1H-tetrazol-5-yl)methoxy]phenyl]methylidene)[1,3]thiazolo[3,2-a]benzimidazol-3(2H)-one
-
(2E)-2-benzylidene[1,3]thiazolo[3,2-a]benzimidazol-3(2H)-one
-
(2E)-2-[(2-oxo-1,2-dihydroquinolin-3-yl)methylidene][1,3]thiazolo[3,2-a]benzimidazol-3(2H)-one
-
(2E)-2-[(5-iodofuran-2-yl)methylidene][1,3]thiazolo[3,2-a]benzimidazol-3(2H)-one
moderate to low inhibition
(2E)-2-[(naphthalen-2-yl)methylidene][1,3]thiazolo[3,2-a]benzimidazol-3(2H)-one
-
(2E)-2-[[2,4-bis(4-methylpiperidin-1-yl)-5-nitrophenyl]methylidene][1,3]thiazolo[3,2-a]benzimidazol-3(2H)-one
-
(2Z)-2-benzylidene[1,3]thiazolo[3,2-a]benzimidazol-3(2H)-one
-
(2Z)-2-ethylidene[1,3]thiazolo[3,2-a]benzimidazol-3(2H)-one
-
(2Z)-2-[(2E)-3-phenylprop-2-en-1-ylidene][1,3]thiazolo[3,2-a]benzimidazol-3(2H)-one
-
(2Z)-2-[(3-phenoxyphenyl)methylidene][1,3]thiazolo[3,2-a]benzimidazol-3(2H)-one
-
(2Z)-2-[(4-chlorophenyl)methylidene][1,3]thiazolo[3,2-a]benzimidazol-3(2H)-one
-
(2Z)-2-[(4-iodophenyl)methylidene][1,3]thiazolo[3,2-a]benzimidazol-3(2H)-one
-
(2Z)-2-[(4-methylphenyl)methylidene][1,3]thiazolo[3,2-a]benzimidazol-3(2H)-one
-
(2Z)-2-[(5-bromofuran-2-yl)methylidene][1,3]thiazolo[3,2-a]benzimidazol-3(2H)-one
-
(2Z)-2-[(5-iodofuran-2-yl)methylidene][1,3]thiazolo[3,2-a]benzimidazol-3(2H)-one
highly selective for NPP1 as compared to other human enzymes, i.e. NPP2, NPP3, NTPDases1-3, TNAP, and eN
(2Z)-2-[(5-methylfuran-2-yl)methylidene][1,3]thiazolo[3,2-a]benzimidazol-3(2H)-one
-
(2Z)-2-[(5-nitrofuran-2-yl)methylidene][1,3]thiazolo[3,2-a]benzimidazol-3(2H)-one
-
(2Z)-2-[(5-phenylfuran-2-yl)methylidene][1,3]thiazolo[3,2-a]benzimidazol-3(2H)-one
-
(2Z)-2-[(furan-2-yl)methylidene][1,3]thiazolo[3,2-a]benzimidazol-3(2H)-one
-
(2Z)-2-[(pyridin-2-yl)methylidene][1,3]thiazolo[3,2-a]benzimidazol-3(2H)-one
-
(2Z)-2-[(thiophen-2-yl)methylidene][1,3]thiazolo[3,2-a]benzimidazol-3(2H)-one
-
(2Z)-2-[[3-(benzyloxy)phenyl]methylidene][1,3]thiazolo[3,2-a]benzimidazol-3(2H)-one
-
(2Z)-2-[[4-(morpholin-4-yl)phenyl]methylidene][1,3]thiazolo[3,2-a]benzimidazol-3(2H)-one
-
(2Z)-2-[[5-(dimethylamino)furan-2-yl]methylidene][1,3]thiazolo[3,2-a]benzimidazol-3(2H)-one
-
(2Z)-2-[[5-(phenylsulfanyl)furan-2-yl]methylidene][1,3]thiazolo[3,2-a]benzimidazol-3(2H)-one
-
(3,5-dimethyl-1H-pyrazol-1-yl) (m-tolyl)methanone
-
(3,5-dimethyl-1H-pyrazol-1-yl) (naphthalen-2-yl)methanone
-
(3,5-dimethyl-1H-pyrazol-1-yl) (o-tolyl)methanone
-
(3,5-dimethyl-1H-pyrazol-1-yl) (pyridin-4-yl)methanone
-
(4-aminophenyl) (3,5-dimethyl-1H-pyrazol-1-yl)methanone
-
(4-aminophenyl) (3,5-dimethyl-4-(p-tolyloxy)-1H-pyrazol-1-yl)methanone
-
(4-aminophenyl) (4-chloro-3,5-dimethyl-1H-pyrazol-1-yl)methanone
-
(4-chloro-3,5-dimethyl-1H-pyrazol-1-yl) (4-chlorophenyl)methanone
-
(4-chloro-3,5-dimethyl-1H-pyrazol-1-yl) (m-tolyl)methanone
-
(4-chloro-3,5-dimethyl-1H-pyrazol-1-yl) (naphthalen-2-yl)methanone
-
(4-chloro-3,5-dimethyl-1H-pyrazol-1-yl) (o-tolyl)methanone
-
(4-chloro-3,5-dimethyl-1H-pyrazol-1-yl) (p-tolyl)methanone
-
(4-chloro-3,5-dimethyl-1H-pyrazol-1-yl) (pyridin-4-yl)methanone
-
(4-chlorophenyl) (3,5-dimethyl-1H-pyrazol-1-yl)methanone
-
(4-chlorophenyl) (3,5-dimethyl-4-(p-tolyloxy)-1H-pyrazol-1-yl)methanone
-
(E)-1-(4-chloro-3,5-dimethyl-1H-pyrazol-1-yl)-3-phenylprop-2-en-1-one
-
(R)-1-(4-chloro-3,5-dimethyl-1H-pyrazol-1-yl)-2-(4-isobutylphenyl)propan-1-one
-
1,1'-(2-(2-bromophenyl)ethene-1,1-diyl)bis(1H-indole)
1-(4-aminobenzoyl)-5-methyl-1H-pyrazol-3(2H)-one
-
1-amino-4-[4-[(4-anilino-6-chloro-1,3,5-triazin-2-yl)amino]-3-sulfoanilino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonic acid
-
1-[(4-methoxyphenyl)methyl]-1H-benzimidazole
-
10-methoxy-6-(5-methoxy-1H-indol-1-yl)indolo[2,1-a]isoquinoline
-
12-methyl-6(3-methyl-1H-indol-1-yl)indolo[1,2-h][1,7]naphthyridine
-
12-methyl-6-(3-methyl-1H-indol-1-yl)indolo[2,1-a]isoquinoline
-
2',3'-cAMP
-
7% inhibition at 2 mM
2',3'-dialdehyde ATP
-
competitive inhibition
2,3-Butanedione
-
inactivation half-life: 21.8 min at 0.1 mM
2,3-dimercapto-1-propanol
2,3-dimethoxy-12-methyl-6-(3-methyl-1H-indol-1-yl)indolo[2,1-a]isoquinoline
-
2-(trifluoromethyl)-3,4,8-tri(4-(trifluoromethyl)phenyl)quinoline
-
2-mercaptoethanol
2-MeSADP
competitive inhibition
2-MeSATP
competitive inhibition
2-methylthioadenosine 5'-triphosphate
-
competitive inhibition
2-[4-[(4-fluorobenzene-1-sulfonyl)oxy]phenyl]-3-[4-[2-(piperidin-1-yl)ethoxy]benzoyl]-1-benzothiophen-6-yl 4-fluorobenzene-1-sulfonate
-
2-[4-[(4-methoxybenzene-1-sulfonyl)oxy]phenyl]-3-[4-[2-(piperidin-1-yl)ethoxy]benzoyl]-1-benzothiophen-6-yl 4-methoxybenzene-1-sulfonate
-
2-[4-[(4-methylbenzene-1-sulfonyl)oxy]phenyl]-3-[4-[2-(piperidin-1-yl)ethoxy]benzoyl]-1-benzothiophen-6-yl 4-methylbenzene-1-sulfonate
38.5% inhibition
2-[4-[(4-tert-butylbenzene-1-sulfonyl)oxy]phenyl]-3-[4-[2-(piperidin-1-yl)ethoxy]benzoyl]-1-benzothiophen-6-yl 4-tert-butylbenzene-1-sulfonate
shows cytotoxicity against MCF-7 and HT-29 cell lines and shows less cytotoxicity on against A-549 cell
2-[4-[(cyclohexanesulfonyl)oxy]phenyl]-3-[4-[2-(piperidin-1-yl)ethoxy]benzoyl]-1-benzothiophen-6-yl cyclohexanesulfonate
30.0% inhibition
2-[4-[(dimethylsulfamoyl)oxy]phenyl]-3-[4-[2-(piperidin-1-yl)ethoxy]benzoyl]-1-benzothiophen-6-yl dimethylsulfamate
43.7% inhibition
2-[4-[(ethanesulfonyl)oxy]phenyl]-3-[4-[2-(piperidin-1-yl)ethoxy]benzoyl]-1-benzothiophen-6-yl ethanesulfonate
35.1% inhibition
2-[4-[(methylsulfamoyl)oxy]phenyl]-3-[4-[2-(piperidin-1-yl)ethoxy]benzoyl]-1-benzothiophen-6-yl methylsulfamate
36.0% inhibition
3',5'-cAMP
-
4% inhibition at 2 mM
3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate
-
competitive inhibition
3,3'-[(2-chlorophenyl)methylene]bis(4-hydroxy-3,4-dihydro-2H-1-benzopyran-2-one)
-
3,4,8-tri(4-fluorophenyl)-2-(trifluoromethyl)quinoline
-
3,4,8-tri([1,1'-biphenyl]-4-yl)-2-(trifluoromethyl)quinoline
-
3,4,8-tri-(3-chlorophenyl)-2-(trifluoromethyl)quinoline
-
3,4,8-tri-m-tolyl-2-(trifluoromethyl)quinoline
-
3,4,8-tri-p-tolyl-2-(trifluoromethyl)quinoline
-
3,4,8-tribromo-2-(trifluoromethyl)quinoline
-
3,4,8-triphenyl-2-(trifluoromethyl)quinoline
-
3,4,8-tris(3,5-dimethylphenyl)-2-(trifluoromethyl)quinoline
-
3,4,8-tris(4-methoxyphenyl)-2-(trifluoromethyl)quinoline
-
3,5-dimethyl-4-(naphthalen-2-yloxy)-1H-pyrazole
-
3,8-dibromo-2-(trifluoromethyl)quinolin-4(1H)-one
3,8-dibromo-4-(piperidin-1-yl)-2-(trifluoromethyl)quinoline
-
3,8-dibromo-4-(pyrrolidin-1-yl)-2-(trifluoromethyl)quinoline
-
3,8-dibromo-4-chloro-2-(trifluoromethyl)quinoline
-
3,8-dibromo-4-N-butylamine-2-(trifluoromethyl)quinoline
-
3,9-difluoro-6-(6-fluoro-1H-indol-1-yl)indolo[2,1-a]isoquinoline
-
3-(3-bromo-4-chloro-2-(trifluoromethyl)quinolin-8-yl)benzonitrile
-
3-bromo-4-chloro-2-(trifluoromethyl)-8-(4-(trifluoromethyl)phenyl)quinoline
-
3-bromo-4-chloro-8-(2,5-dimethoxyphenyl)-2-(trifluoromethyl)quinoline
-
3-bromo-4-chloro-8-(3,5-difluorophenyl)-2-(trifluoromethyl)quinoline
-
3-bromo-4-chloro-8-(3,5-dimethylphenyl)-2-(trifluoromethyl)quinoline
-
3-bromo-4-chloro-8-(4-methoxyphenyl)-2-(trifluoromethyl)quinoline
-
3-bromo-4-chloro-8-(o-tolyl)-2-(trifluoromethyl)quinoline
-
3-bromo-4-chloro-8-(thiophen-3-yl)-2-(trifluoromethyl)quinoline
-
3-bromo-4-chloro-8-phenyl-2-(trifluoromethyl)quinoline
-
3-bromo-4-N-butylamine-8-(4-methoxyphenyl)-2-(trifluoromethyl)quinoline
-
3-chloropentane-2,4-dione
-
3-fluoro-12-methyl-6-(3-methyl-1H-indol-1-yl)indolo[2,1-a]isoquinoline
-
3-fluoro-6-(1H-pyrrolo[2,3-b]pyridin-1-yl)pyrido[3',2':4,5]pyrrolo[2,1-a]isoquinoline
-
3-methyl-2-(4-methylbenzoyl)-1,2-dihydropyrazol-5-one
-
4,4'-diisothiocyanatostilbene-2,2' disulfonic acid
-
P2-purinoceptor antagonist, less potent inhibition, IC50: 0.022 mM
4-(3,8-dibromo-2-(trifluoromethyl)quinolin-4-yl)morpholine
-
4-(3-[4-[2-(piperidin-1-yl)ethoxy]benzoyl]-6-[(quinoline-8-sulfonyl)oxy]-1-benzothiophen-2-yl)phenyl quinoline-8-sulfonate
28.7 inhibition; 42.5% inhibition
4-(3-[4-[2-(piperidin-1-yl)ethoxy]benzoyl]-6-[[4-(trifluoromethyl)benzene-1-sulfonyl]oxy]-1-benzothiophen-2-yl)phenyl 4-(trifluoromethyl)benzene-1-sulfonate
-
4-(4-chlorobenzamido)phenyl 2,4,6-tri(propan-2-yl)benzene-1-sulfonate
-
4-(4-chlorobenzamido)phenyl 4-(trifluoromethyl)benzene-1-sulfonate
-
4-(4-chlorobenzamido)phenyl 4-fluorobenzene-1-sulfonate
46% inhibition at 0.1 mM
4-(4-chlorobenzamido)phenyl 4-methylbenzene-1-sulfonate
-
4-(4-chlorobenzamido)phenyl 4-tert-butylbenzene-1-sulfonate
-
4-(4-chlorobenzamido)phenyl benzenesulfonate
-
4-chloro-2-(trifluoromethyl)-3,8-bis(4-(trifluoromethyl)phenyl)quinoline
-
4-chloro-3,8-bis(3-methylphenyl)-2-(trifluoromethyl)quinoline
-
4-chloro-3,8-bis(4-(trifluoromethoxy)phenyl)-2-(trifluoromethyl)quinoline
-
4-chloro-3,8-bis(4-methoxyphenyl)-2-(trifluoromethyl)quinoline
-
4-chloro-3,8-diphenyl-2-(trifluoromethyl)quinoline
-
4-chloro-8-(2,5-dimethoxyphenyl)-2-(trifluoromethyl)-3-(4-(trifluoromethyl)phenyl)quinoline
-
4-chloro-8-phenyl-2-(trifluoromethyl)-3-(4-(trifluoromethyl)phenyl)quinoline
-
4-N-butylamine-3,8-bis(4-methoxyphenyl)-2-(trifluoromethyl)quinoline
-
4-[(cycloheptanecarbonyl)amino]phenyl 2,4,6-tri(propan-2-yl)benzene-1-sulfonate
29% inhibition at 0.1 mM; 37% inhibition at 0.1 mM
4-[(cycloheptanecarbonyl)amino]phenyl 4-(trifluoromethyl)benzene-1-sulfonate
-
4-[(cycloheptanecarbonyl)amino]phenyl 4-fluorobenzene-1-sulfonate
39.3% inhibition at 0.1 mM
4-[(cycloheptanecarbonyl)amino]phenyl 4-methylbenzene-1-sulfonate
-
4-[(cycloheptanecarbonyl)amino]phenyl 4-tert-butylbenzene-1-sulfonate
-
4-[(cycloheptanecarbonyl)amino]phenyl benzenesulfonate
-
4-[(cyclohexanecarbonyl)amino]phenyl 4-(trifluoromethyl)benzene-1-sulfonate
-
4-[(cyclohexanecarbonyl)amino]phenyl 4-fluorobenzene-1-sulfonate
-
4-[(cyclohexanecarbonyl)amino]phenyl 4-methylbenzene-1-sulfonate
39% inhibition at 0.1 mM+L345; 43% inhibition at 0.1 mM
4-[(cyclohexanecarbonyl)amino]phenyl 4-tert-butylbenzene-1-sulfonate
-
4-[(cyclohexanecarbonyl)amino]phenyl benzenesulfonate
-
4-[(cyclohexanecarbonyl)amino]phenyl ethanesulfonate
-
4-[(cyclohexanecarbonyl)amino]phenyl methanesulfonate
-
4-[(cyclohexanecarbonyl)amino]phenyl propane-1-sulfonate
-
4-[(cyclooctanecarbonyl)amino]phenyl 2,4,6-tri(propan-2-yl)benzene-1-sulfonate
30% inhibition at 0.1 mM; 30% inhibition at 0.1 mM
4-[(cyclooctanecarbonyl)amino]phenyl 4-(trifluoromethyl)benzene-1-sulfonate
29% inhibition at 0.1 mM
4-[(cyclooctanecarbonyl)amino]phenyl 4-methylbenzene-1-sulfonate
35% inhibition at 0.1 mM; 43% inhibition at 0.1 mM
4-[(cyclooctanecarbonyl)amino]phenyl 4-tert-butylbenzene-1-sulfonate
40% inhibition at 0.1 mM; 46% inhibition at 0.1 mM
4-[(cyclooctanecarbonyl)amino]phenyl benzenesulfonate
45% inhibition at 0.1 mM; 47% inhibition at 0.1 mM
4-[(cyclopentanecarbonyl)amino]phenyl 4-(trifluoromethyl)benzene-1-sulfonate
-
4-[(cyclopentanecarbonyl)amino]phenyl 4-fluorobenzene-1-sulfonate
-
4-[(cyclopentanecarbonyl)amino]phenyl 4-methylbenzene-1-sulfonate
-
4-[(cyclopentanecarbonyl)amino]phenyl 4-tert-butylbenzene-1-sulfonate
-
4-[(cyclopentanecarbonyl)amino]phenyl benzenesulfonate
-
4-[(naphthalene-2-carbonyl)amino]phenyl 2,4,6-tri(propan-2-yl)benzene-1-sulfonate
-
4-[(naphthalene-2-carbonyl)amino]phenyl 4-(trifluoromethyl)benzene-1-sulfonate
-
4-[(naphthalene-2-carbonyl)amino]phenyl 4-fluorobenzene-1-sulfonate
-
4-[(naphthalene-2-carbonyl)amino]phenyl 4-tert-butylbenzene-1-sulfonate
49% inhibition at 0.1 mM
4-[(naphthalene-2-carbonyl)amino]phenyl benzenesulfonate
23% inhibition at 0.1 mM; 24% inhibition at 0.1 mM
4-[(quinoline-8-carbonyl)amino]phenyl 2,4,6-tri(propan-2-yl)benzene-1-sulfonate
37% inhibition at 0.1 mM; 42% inhibition at 0.1 mM
5'-ADP
5'-AMP
5'-O-(boranyl[[hydroxy(phosphonomethyl)phosphoryl]oxy]phosphoryl)adenosine
-
5'-O-[([[dibromo(phosphono)methyl](hydroxy)phosphoryl]oxy)(hydroxy)phosphoryl]-N,N-diethyladenosine
-
5'-phosphoadenosine 3'-phosphate
-
P2-purinoceptor antagonist, less potent inhibitor, IC50: 0.036 mM
5,5'-(propane-1,3-diyl)di(1,3,4-oxadiazole-2(3H)-thione)
-
5-(1H-pyrazol-1-yl)pyrazolo[5,1-a]isoquinoline
-
5-(1H-pyrrol-1-yl)pyrrolo[2,1-a]isoquinoline
-
6-(1H-benzo[d]imidazol-1-yl)benzo[4,5]imidazo[2,1-a]isoquinoline
-
6-(1H-indol-1-yl)indolo[2,1-a]isoquinoline
-
6-(1H-pyrrolo[2,3-b]pyridin-1-yl)pyrido[3',2':4,5]pyrrolo[2,1-a]isoquinoline
-
6-(4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)-9,10-dihydroindolo[2,1-a]isoquinolin-11(8H)-one
-
6-(5-cyano-1H-indol-1-yl)-2,3-dimethoxyindolo[2,1,-a]isoquinoline-10-carbonitrile
-
6-(5-cyano-1H-indol-1-yl)-3-fluoroindolo[2,1-a]isoquinoline-10-carbonitrile
-
6-(5-cyano-1H-indol-1-yl)indolo[2,1-a]isoquinoline-10-carbonitrile
-
8,8'-[carbonylbis[azanediyl-3,1-phenylenecarbonylazanediyl(4-methyl-3,1-phenylene)carbonylazanediyl]]di(naphthalene-1,3,5-trisulfonic acid)
-
8,9-dimethoxy-5-(1H-pyrrol-1-yl)pyrrolo[2,1-a]isoquinoline
-
8-(4-methoxyphenyl)-3,4-di-p-tolyl-2-(trifluoromethyl)quinoline
-
8-phenyl-2-(trifluoromethyl)-3,4-bis(4-(trifluoromethyl)phenyl)quinoline
-
8-phenyl-4-(p-tolyl)-2-(trifluoromethyl)-3-(4-(trifluoromethyl)phenyl)quinoline
-
9-fluoro-6-(6-fluoro-1H-indol-1-yl)-2,3-dimethoxyindolo[2,1-a]isoquinoline
-
9-fluoro-6-(6-fluoro-1H-indol-1-yl)-[1,3]dioxolo[4,5-g]indolo[2,1-a]isoquinoline
-
9-fluoro-6-(6-fluoro-1H-indol-1-yl)indolo[2,1-a]isoquinoline
-
acidic fibroblast growth factor
-
potent inhibition at nearly stoichiometric concentrations, Ki: 1.3 nM
-
adenosine
-
competitive inhibition, Ki: 2.7 mM
adenosine 2'-monophosphate
-
8% inhibition at 2 mM
adenosine 3',5'-bisphosphate
-
-
adenosine 3'-monophosphate
adenosine 5'-alpha,beta-methylene-gamma-thiotriphosphate
-
adenosine 5'-sulfate
Adenyl-5'-yl imidodiphosphate
adenylic acid
-
competitive inhibition, Ki: 0.036 mM
ADP-ribose
-
47% inhibition at 0.5 mM, competitive type of inhibition
alpha,beta-metADP
alpha,beta-metATP
alpha,beta-methylene adenosine 5'-triphosphate
alpha,beta-methylene ADP
-
mixed inhibition
alpha,beta-methylene ATP
-
competitive inhibition
alpha,beta-methyleneadenosine triphosphate
cannot be hydrolyzed and blocks both NTPase and pyrophosphatase activities
alpha-borano-beta,gamma-MetATP
-
AMP(CH)2PP
-
competitive inhibition, Ki: 25 mM
AMP-amidate
-
competitive inhibition, Ki: 30 mM
AMP-PP(S)
-
competitive inhibition, Ki: 33 mM
B4 lectin
-
from Vicia villosa, strong inhibition between 0.002-0.02 mM, specific for hydrolysis of UDP-N-acetyl-alpha-D-galactosamine, reversal by addition of N-acetyl-alpha-D-galactosamine, only weakly inhibitory towards UDP-galactose or UDP-GlcNAc
-
benzoyl-ATP
beta,gamma-methyleneadenosine 5'-triphosphate
-
competitive inhibition of formycin 5'-triphosphate hydrolysis, Ki: 0.1 mM
Borate
-
strong inhibition at pH 8.5, not at pH 7.4
CDP-choline
-
62% inhibition at 0.2 mM
Cibacron blue
coenzyme A
-
90% inhibition at 0.2 mM
CTP
Ovis aries aries
-
potent inhibition at 0.1 mM
cytidine 5'-diphosphate
-
competitive inhibition, Ki: 0.0085 mM
dAMP
-
16% inhibition at 17 mM
di-2'-deoxyadenosine 5',5''-P1,P5,alpha,beta-methylene-delta,epsilon-methylene-pentaphosphate-gamma-borano
di-2'-deoxyadenosine 5',5''-P1,P5,alpha,beta-methylene-gamma,delta-methylene-tetraphosphate
-
diadenosine 5',5''-P1,P5,alpha,beta-methylene-delta,epsilon-methylene-pentaphosphate-gamma-borano
-
dialADP
noncompetitive inhibition
dialATP
diethyldiphosphate
-
inactivation follows apparent first-order kinetics, completely restored by hydroxylamine
diphosphate
dithiothreitol
EGTA
-
strong inhibition at 1 mM, partially reversed by Mg2+, complete reactivation at 10 mM Ca2+
ethyl 3-oxobutanoate
-
F-
-
0.01 mM, 54% inhibition
FeSO4
Ovis aries aries
-
42% inhibition at 1 mM in the presence of 0.1 mM o-phenanthroline
gamma-S-adenosine 5'-(alpha,beta-methylene)triphosphate
competitive inhibition
GDP
-
competitive inhibition, Ki: 0.0025 mM
GDP-mannose
-
competitive inhibition of phosphodiesterase activity
glycine
-
-
GSH
Ovis aries aries
-
40% inhibition at 1 mM
GSSG
Ovis aries aries
-
25% inhibition at 1 mM
guanidine hydrochloride
-
85% inhibition at 4.2 M, complete recovery of activity after dialysis
heparan sulfate
-
NPP1
heparin
ITP
Ovis aries aries
-
potent inhibition at 0.1 mM
L-ascorbic acid
-
8% inhibition at 16 mM
L-cysteine
L-phenylalanine
-
5 mM, 10% loss of activity
lectin
-
from Wistaria floribunda, inhibition for hydrolysis of UDP-N-acetyl-alpha-D-galactosamine, reversal by addition of N-acetyl-alpha-D-galactosamine
-
N-(3,4-dimethoxyphenyl)-2-[(5-methoxy-3H-imidazo[4,5-b]pyridin-2-yl)sulfanyl]acetamide
-
N-ethyl-5-phenylisoxazolium-3'-sulfonate
-
Woodward's reagent, inactivation half-life: 16 min at 0.05 mM
N-omega-nitro-L-arginine methyl ester
-
enzyme activity is decreased in serum and platelets from N-omega-nitro-L-arginine methyl ester -treated rats
N-[2-[1-(6,7-dimethoxyquinazolin-4-yl)piperidin-4-yl]ethyl] sulfuric diamide
i.e. SAR 03004
N-[2-[1-(6,7-dimethoxyquinazolin-4-yl)piperidin-4-yl]ethyl]sulfuric diamide
-
N1-butylnicotinamide chloride
-
competitive inhibition, Ki: 0.408 mM
N1-heptylnicotinamide chloride
-
competitive inhibition, Ki: 0.48 mM
N1-hexylnicotinamide chloride
-
competitive inhibition, Ki: 0.629 mM
N1-octylnicotinamide chloride
-
competitive inhibition, Ki: 0.287 mM
N1-pentylnicotinamide chloride
-
competitive inhibition, Ki: 0.297 mM
nicotinamide
-
19% inhibition at 100 mM
NMN
-
10% inhibition at 40 mM
nucleoside monophosphates
-
-
o-phenanthroline
p-hydroxymercuribenzoate
Ovis aries aries
-
60% inhibition at 1 mM, reversal by GSH
p-nitrophenyl 3'-thymidylate
-
15% inhibition at 0.2 mM
p-nitrophenyl 5'-thymidylate
-
15% inhibition at 0.2 mM
P1,P4-bis(5'-adenosyl)-alpha,beta-gamma,delta-bismethylene-tetraphosphate
-
Pentane-2,4-dione
-
phosphate
polyoxymetalate PSB-POM141
-
-
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid
pyridoxal phosphate-6-azophenyl-2',4'disulfonic acid
PZB08513136A
the most potent thioacetamide derivative
Reactive blue 2
SDS
-
partial inactivation at 0.1%, w/v, complete inactivation at 1%, w/v
Sodium diphosphate
Sodium fluoride
-
about 30% residual activity at 40 mM sodium fluoride using ATP as substrate, less than 60% residual activity at 40 mM sodium fluoride using ADP or bis(4-nitrophenyl) phosphate as substrate
suramin
thiamine diphosphate
-
17% inhibition at 0.2 mM
thiazolobenzimidazolone
and derivatives
TTP
Ovis aries aries
-
70% inhibition at 1 mM
UDP-galactose
-
competitive inhibition, Ki: 29 mM
UDP-glucose
uridine 5'-diphosphate
-
competitive inhibition, Ki: 0.0012 mM
UTP
Ovis aries aries
-
potent inhibition at 0.1 mM
[TiW11CoO40]8-
i.e. PSB-POM141
-
additional information
-